Market Place
Sourcing Support
Bellerophon lets almost all employees go, looks for deals in wake of PhIII flop
30 Jun 2023 //
ENDPTS
Bellerophon’s study of fILD therapy fails to meet primary endpoint
06 Jun 2023 //
CLINICAL TRIALS ARENA
Bellerophon Announces Top-Line Data from Ph 3 REBUILD Clinical Trial of INOpulse
05 Jun 2023 //
GLOBENEWSWIRE
Bellerophon`s stock tanks as inhaled drug-device fails to redeem itself
05 Jun 2023 //
ENDPTS
Bellerophon Provides Clinical Program Update and Reports 1Q 2023 FYR Results
15 May 2023 //
GLOBENEWSWIRE
Bellerophon Announces Last Patient Has Completed Blinded Treatment in PIII REBUILD Study
11 May 2023 //
GLOBENEWSWIRE
Bellerophon Provides Clinical Program Update & Reports Full-Year 2022 FYR
31 Mar 2023 //
GLOBENEWSWIRE
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
06 Mar 2023 //
GLOBENEWSWIRE
Bellerophon Receives IND Clearance from NMPA to Conduct PIII Trial for INOpulse
09 Feb 2023 //
GLOBENEWSWIRE
Bellerophon completes subject enrolment in lung disease trial
19 Jan 2023 //
CLINICAL TRIALS ARENA
Bellerophon Announce Completion of Enrollment in PIII REBUILD Study for INOpulse
18 Jan 2023 //
GLOBENEWSWIRE
Bellerophon Announces License Agreement for the Commercialization of INOpulse
05 Jan 2023 //
GLOBENEWSWIRE
The 357 Company Launches 357 Canna Logistics for International Cannabis Shipping
14 Nov 2022 //
GLOBENEWSWIRE
Bellerophon Provides Clinical Update and Reports Q3 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3
27 Sep 2022 //
GLOBENEWSWIRE
Bellerophon Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Bellerophon Announces Poster Presentation at Upcoming ATS 2022
12 May 2022 //
GLOBENEWSWIRE
Bellerophon Provides Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
10 Jan 2022 //
GLOBENEWSWIRE
Bellerophon Provides Clinical Program Update
05 Aug 2021 //
GLOBENEWSWIRE
Bellerophon Announces Results of Interim Analysis of Phase 3 COViNOX
23 Nov 2020 //
GLOBENEWSWIRE
Bellerophon Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study
15 Jul 2020 //
GLOBENEWLSWIRE
Bellerophon Therapeutics Announces First Patient Treated in Pha3 Clinical Study
13 Jul 2020 //
GLOBENEWSWIRE
FDA opens up Bellerophon`s gas therapy for COVID-19, stock rockets
20 Mar 2020 //
FIERCEBIOTECH
Bellerophon Signs Agreement with the FDA on its Planned Pivotal Phase 3 Study
10 Mar 2020 //
BIO SPACE
Bellerophon Announces Positive Top-line Results of Ph 2/3 Study of INOpulse
17 Dec 2019 //
BIO SPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.